Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-088622
Filing Date
2025-06-20
Accepted
2025-06-20 18:44:30
Documents
1
Period of Report
2025-06-17

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 3827
  Complete submission text file 0000950170-25-088622.txt   5271
Mailing Address C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT NOVATO CA 94949
Business Address
Sharp Shalini (Reporting) CIK: 0001377202 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-42382 | Film No.: 251062647

Mailing Address 250 EAST GRAND AVENUE, SUITE 65 SOUTH SAN FRANCISCO CA 94080
Business Address 250 EAST GRAND AVENUE, SUITE 65 SOUTH SAN FRANCISCO CA 94080 650-338-3533
Septerna, Inc. (Issuer) CIK: 0001984086 (see all company filings)

EIN.: 843891440 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)